Last Week aTyr Pharma, Inc. (NASDAQ:LIFE) Ratings

May 17, 2018 - By Michele Cranor

aTyr Pharma, Inc. (NASDAQ:LIFE) Corporate Logo

aTyr Pharma, Inc. (NASDAQ:LIFE) Ratings Coverage

A total of 3 analysts rate aTyr Pharma (NASDAQ:LIFE) as follows: 0 “Buy”, 0 “Hold” and 3 “Sell”. Тherefore 0 are bullish. (NASDAQ:LIFE) has 3 ratings reports on May 17, 2018 according to StockzIntelligence. On Wednesday, February 14 the stock of aTyr Pharma, Inc. (NASDAQ:LIFE) earned “Sell” rating by J.P. Morgan. On Wednesday, February 14 the rating was downgraded by JP Morgan to “Underweight”. On Tuesday, May 15 Citigroup downgraded aTyr Pharma, Inc. (NASDAQ:LIFE) to “Sell” rating. Listed here are aTyr Pharma, Inc. (NASDAQ:LIFE) PTs and latest ratings.

15/05/2018 Broker: Citigroup Rating: Sell New Target: $1.0000 Downgrade
14/02/2018 Broker: J.P. Morgan Rating: Sell Downgrade
14/02/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Underweight Downgrade

The stock increased 11.20% or $0.1 during the last trading session, touching $0.95.aTyr Pharma, Inc. has 1.04 million shares volume, 681.58% up from normal. LIFE is downtrending and has moved 19.01% since May 17, 2017. The stock underperformed the S&P 500 by 30.56%.

aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of Physiocrine therapeutics for patients suffering from severe and rare diseases.The firm is worth $28.17 million. The firm develops Resolaris, which is in Phase Ib/II clinical trials for treating patients with facioscapulohumeral muscular dystrophy , early onset FSHD, and limb-girdle muscular dystrophy, as well as under evaluation to treat Duchenne muscular dystrophy.Last it reported negative earnings. The Company’s discovery program includes Stalaris for treating interstitial lung disease with an immune component; and preclinical research program comprises Project ORCA to treat therapeutic applications of Physiocrines.

For more aTyr Pharma, Inc. (NASDAQ:LIFE) news announced recently go to: Nasdaq.com, Benzinga.com, Nasdaq.com, Seekingalpha.com or Benzinga.com. The titles are as follows: “aTyr Pharma Presents Poster on Preclinical Data from ATYR1923 Program at American Thoracic Society 2018 …” announced on May 17, 2018, “Benzinga Pro’s 5 Stocks To Watch Today” on May 17, 2018, “Mid-Afternoon Market Update: Precipio Surges Following Strong Preliminary Q1 Results; aTyr Pharma Shares Slide” with a publish date: May 14, 2018, “Premarket analyst action – healthcare” and the last “Benzinga’s Daily Biotech Pulse: Verastem Uprooted On Stock Offering, Titan Pharma Earnings” with publication date: May 16, 2018.

aTyr Pharma, Inc. (NASDAQ:LIFE) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.